Recently, we have demonstrated that diabetes-induced upregulation in kidney GLUT2 expression and dynamic translocation is mitigated by peripheral pharmacological blockade or genetic deletion of CB1R in RPTCs, and that it reduces glucose reabsorption and prevents the development of DKD25. The gene discussed is SLC2A2; the disease is diabetes mellitus.